Your browser doesn't support javascript.
loading
Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective Cohort.
Rodrigues, Filipe Brogueira; Abreu, Daisy; Damásio, Joana; Goncalves, Nilza; Correia-Guedes, Leonor; Coelho, Miguel; Ferreira, Joaquim J.
Afiliação
  • Rodrigues FB; Clinical Pharmacology Unit Instituto de Medicina Molecular Lisbon Portugal.
  • Abreu D; Laboratory of Clinical Pharmacology and Therapeutics Faculty of Medicine University of Lisbon Lisbon Portugal.
  • Damásio J; Clinical Pharmacology Unit Instituto de Medicina Molecular Lisbon Portugal.
  • Goncalves N; Laboratory of Clinical Pharmacology and Therapeutics Faculty of Medicine University of Lisbon Lisbon Portugal.
  • Correia-Guedes L; Neurology Department Hospital de Santo António-Centro Hospitalar do Porto Porto Portugal.
  • Coelho M; Clinical Pharmacology Unit Instituto de Medicina Molecular Lisbon Portugal.
  • Ferreira JJ; Laboratory of Clinical Pharmacology and Therapeutics Faculty of Medicine University of Lisbon Lisbon Portugal.
Mov Disord Clin Pract ; 4(5): 737-742, 2017.
Article em En | MEDLINE | ID: mdl-30363513
BACKGROUND: Huntington's disease (HD) is a rare and fatal inherited genetic disorder characterized by progressive motor, cognitive, and behavioral impairment. It leads to premature death, but data regarding advanced-stage disease are scarce. We sought to determine HD-associated survival, mortality, and causes and places of death. METHODS: Data from the European HD Network prospective study (REGISTRY) collected from 2001 through 2013 were used, including the Unified Huntington's Disease Rating Scale and death report forms. Group comparisons were performed using the t test or the χ2 test. Survival analyses were computed through Kaplan-Meier estimates of median survival. All tests were 2-sided with a significance level of P = 0.05. RESULTS: In total, 5164 participants were analyzed. The mean age at diagnosis was 49 years, and the mean age at death was 58 years. At the end of the study period, there were 533 deaths (10.3% of patients). Median survival was 24 years from diagnosis and 35 years from symptom onset. The most frequent causes of death were pneumonia (19.5%), other infections (6.9%), and suicide (6.6%). The most frequent places of death were the hospital (29.8%), the home (23.9%), and nursing houses (19.8%). CONCLUSIONS: Patients with HD tend to die from the same conditions as patients with other neurodegenerative diseases. However, compared with nonhereditary Parkinson's disease and Alzheimer's disease, the median time from onset to death is longer, and the places of death are distinctive.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Mov Disord Clin Pract Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Mov Disord Clin Pract Ano de publicação: 2017 Tipo de documento: Article